A Polymorphic Variant of AFAP-110 Enhances

Enhanced expression and activity of cSrc are associated with ovarian cancer progression. Generally, cSrc does not contain activating mutations; rather, its activity is increased in response to signals that affect a conformational change that releases its autoinhibition. In this report, we analyzed ovarian cancer tissues for the expression of a cSrc-activating protein, AFAP-110. AFAP-110 activates cSrc through a direct interaction that releases it from its autoinhibited conformation. Immunohistochemical analysis revealed a concomitant increase of AFAP-110 and cSrc in ovarian cancer tissues. An analysis of the AFAP-110 coding sequence revealed the presence of a nonsynonymous, single-nucleotide polymorphism that resulted in a change of Ser403 to Cys403. In cells that express enhanced levels of cSrc, AFAP-110 403C directed the activation of cSrc and the formation of podosomes independently of input signals, in contrast to wild-type AFAP-110. We therefore propose that, under conditions of cSrc overexpression, the polymorphic variant of AFAP-110 promotes cSrc activation. Further, these data indicate a mechanism by which an inherited genetic variation could influence ovarian cancer progression and could be used to predict the response to targeted therapy.

[1]  E. Bruera,et al.  Molecular epidemiology, cancer-related symptoms, and cytokines pathway. , 2008, The Lancet. Oncology.

[2]  J. Cunnick,et al.  Podosomes and Invadopodia: Related structures with Common Protein Components that May Promote Breast Cancer Cellular Invasion , 2008, Breast cancer : basic and clinical research.

[3]  C. Stehlik,et al.  AFAP‐110 is required for actin stress fiber formation and cell adhesion in MDA‐MB‐231 breast cancer cells , 2007, Journal of cellular physiology.

[4]  S. Weed,et al.  PI3K activation is required for PMA-directed activation of cSrc by AFAP-110. , 2007, American journal of physiology. Cell physiology.

[5]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[6]  G. Gallick,et al.  Treatment for Advanced Tumors: Src Reclaims Center Stage , 2006, Clinical Cancer Research.

[7]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[8]  Christopher C Taylor,et al.  SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. , 2005, Cancer research.

[9]  David B. Goldstein,et al.  Genomics: Understanding human diversity , 2005, Nature.

[10]  D. Montell,et al.  Ovarian Cancer Metastasis: Integrating insights from disparate model organisms , 2005, Nature Reviews Cancer.

[11]  Yolande Pengetnze,et al.  Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. , 2005, Molecular cancer therapeutics.

[12]  S. Weed,et al.  Protein Kinase Cα Activates c-Src and Induces Podosome Formation via AFAP-110 , 2004, Molecular and Cellular Biology.

[13]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[14]  M. Frame,et al.  Newest findings on the oldest oncogene; how activated src does it , 2004, Journal of Cell Science.

[15]  D. Flynn,et al.  Analysis of the role of the leucine zipper motif in regulating the ability of AFAP‐110 to alter actin filament integrity , 2004, Journal of cellular biochemistry.

[16]  M. Aepfelbacher,et al.  Podosomes: adhesion hot-spots of invasive cells. , 2003, Trends in cell biology.

[17]  Peter F Thall,et al.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. , 2003, Gynecologic oncology.

[18]  Xianglin Shi,et al.  PC phosphorylation increases the ability of AFAP-110 to cross-link actin filaments. , 2002, Molecular biology of the cell.

[19]  M. Lemmon,et al.  Pleckstrin homology domains and the cytoskeleton , 2002, FEBS letters.

[20]  B. Jiang,et al.  The intrinsic ability of AFAP-110 to alter actin filament integrity is linked with its ability to also activate cellular tyrosine kinases , 2001, Oncogene.

[21]  D. Haussler,et al.  A physical map of the human genome , 2001, Nature.

[22]  Jonathan A. Cooper,et al.  Src family kinases are required for integrin but not PDGFR signal transduction , 1999, The EMBO journal.

[23]  D. Flynn,et al.  Monoclonal antibodies directed against AFAP-110 recognize species-specific and conserved epitopes. , 1999, Hybridoma.

[24]  P. Sigler,et al.  Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Brass,et al.  Protein Kinase C Regulates Pleckstrin by Phosphorylation of Sites Adjacent to the N-terminal Pleckstrin Homology Domain (*) , 1995, The Journal of Biological Chemistry.

[26]  M Wilmanns,et al.  Structure of the binding site for inositol phosphates in a PH domain. , 1995, The EMBO journal.

[27]  Michael Nilges,et al.  Structure of the pleckstrin homology domain from β-spectrin , 1994, Nature.

[28]  P. Hajduk,et al.  Solution structure of a pleckstrin-homology domain , 1994, Nature.

[29]  J. Thompson,et al.  The PH domain: a common piece in the structural patchwork of signalling proteins. , 1993, Trends in biochemical sciences.

[30]  B. Hemmings,et al.  Pleckstrin domain homology , 1993, Nature.

[31]  D. Baltimore,et al.  A putative modular domain present in diverse signaling proteins , 1993, Cell.

[32]  J. Parsons,et al.  Tyrosine phosphorylation of a 120-kilodalton pp60src substrate upon epidermal growth factor and platelet-derived growth factor receptor stimulation and in polyomavirus middle-T-antigen-transformed cells , 1991, Molecular and cellular biology.

[33]  Parsons Sj,et al.  Local degradation of fibronectin at sites of expression of the transforming gene product pp60src. , 1985 .